This site is intended for healthcare professionals
RET Inhibition
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers


Read time: 270 mins
Last updated:10th Sep 2021
Published:10th Sep 2021

RET inhibitors are an exciting development for non-small cell lung cancer (NSCLC) and thyroid cancers.

  • Discover how RET inhibitors work and review summaries of their efficacy and safety
  • Our leading experts Dr Alexander Drilon and Professor Lori Wirth highlight the importance of testing for RET gene alterations
  • Hear from Professor Fernando Lopez-Rios, an expert pathologist, on improving and interpreting molecular test outcomes

Professor Fernando Lopez-Rios, a professor of Pathology and Molecular Pathology at Universidad CEU San Pablo in Madrid, Spain, highlights why it is important to learn about testing for rearranged during transfection (RET) gene alterations in patients with non-small cell lung cancer (NSCLC) and thyroid cancer.

The RET inhibitors selpercatinib and pralsetinib present novel treatment opportunities for NSCLC and thyroid cancer patients harbouring alterations in the proto-oncogene RET

Throughout the Learning Zone, leading experts in the field of NSCLC (Dr Alexander Drilon) and thyroid cancer (Professor Lori Wirth) discuss the impact of RET gene alterations on the treatment options available for their patients. Professor Lopez-Rios shares insights into molecular testing techniques used to identify RET alterations, tips for successful test outcomes, and how to interpret results.

Learn how to identify patients who may be eligible for RET inhibition and find out how to monitor and manage possible side effects.

Meet the experts

Dr Alexander Drilon

Dr Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, USA.

Expert opinion - impact of RET inhibitors for NSCLC

Professor Lori Wirth

Professor Lori Wirth is Associate Professor of Medicine at Harvard Medical School and Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, USA.

Expert opinion - RET inhibitors in the management of thyroid cancers

Professor Fernando Lopez-Rios

Professor Fernando Lopez-Rios is full professor of Pathology and Molecular Pathology at the Department of Medical Sciences, San Pablo CEU University, Madrid, Spain.

Expert opinion - molecular testing for RET alterations